Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Business Wire
Improves cost of capital Increases committed capital to a total facility size of $215M CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris $200.0 million of capital at close and the ability to draw down another $15.2 million to redeem Xeris’ outstanding 5.00% convertible senior notes due 2025.“We are very pleased with the outcome of this refinancing transaction with Hayfin. This upsized facility, along with cash generation from our existing products and partnerships, allows us greater flexibility to continue to invest in the growth of our business. In addition to the new capital, we reduced our borrowing inte
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
- Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions [Yahoo! Finance]Yahoo! Finance
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire
XERS
Earnings
- 3/6/24 - Miss
XERS
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- XERS's page on the SEC website